In the first half of 2022, Xiaoke pill held a share of more than 23 percent in the public healthcare market in China, ranked first among diabetes drugs. Meanwhile, Yiling Pharmaceutical’s Jinlida granule remained an important diabetes drug.
…. more: Statista.com (Quelle/Source)